Overview

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Status:
Withdrawn

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels after a meal. Lowering high sugar levels and fat levels after a meal is very important in the prevention of the problems that persons with type 2 diabetes often encounter. Hypothesis is that Pramlintide will lower blood sugar and fat levels after a meal.

Phase:

N/A

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Collaborator:

Amylin Pharmaceuticals, LLC.

Treatments:

Islet Amyloid Polypeptide
Pramlintide